WO2006076387A3 - Cyanidin-3-glucoside as an anti-neoplastic agent - Google Patents

Cyanidin-3-glucoside as an anti-neoplastic agent Download PDF

Info

Publication number
WO2006076387A3
WO2006076387A3 PCT/US2006/000883 US2006000883W WO2006076387A3 WO 2006076387 A3 WO2006076387 A3 WO 2006076387A3 US 2006000883 W US2006000883 W US 2006000883W WO 2006076387 A3 WO2006076387 A3 WO 2006076387A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyanidin
glucoside
neoplastic
activation
markers
Prior art date
Application number
PCT/US2006/000883
Other languages
French (fr)
Other versions
WO2006076387A2 (en
Inventor
Min Ding
Original Assignee
Represented By The Secretary O
Min Ding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Represented By The Secretary O, Min Ding filed Critical Represented By The Secretary O
Publication of WO2006076387A2 publication Critical patent/WO2006076387A2/en
Publication of WO2006076387A3 publication Critical patent/WO2006076387A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This disclosure concerns the discovery that cyanidin-3-glucoside inhibits neoplastic transformation, metastasis, neoplastic cell migration and invasion, activation of tumor cell markers {e.g., NF-κB, AP-I, COX-2, TNF-α and MAPK), activation of cell migration markers (e.g., JNK, p38, and ERK), and induces apoptosis in neoplastic cell (such as HL-60 cells). Cyanidin-3-glucoside is also demonstrated to possess strong antioxidant activity involving, at least, inhibition reactive oxygen species and induction of cytoprotective genes.
PCT/US2006/000883 2005-01-11 2006-01-10 Cyanidin-3-glucoside as an anti-neoplastic agent WO2006076387A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64337105P 2005-01-11 2005-01-11
US60/643,371 2005-01-11

Publications (2)

Publication Number Publication Date
WO2006076387A2 WO2006076387A2 (en) 2006-07-20
WO2006076387A3 true WO2006076387A3 (en) 2006-08-24

Family

ID=36282558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000883 WO2006076387A2 (en) 2005-01-11 2006-01-10 Cyanidin-3-glucoside as an anti-neoplastic agent

Country Status (1)

Country Link
WO (1) WO2006076387A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2349311C1 (en) * 2007-08-02 2009-03-20 Михаил Владимирович Кутушов Application of naphthalene derivative as oncological disease treatment medicine
US8137714B2 (en) 2008-07-25 2012-03-20 Mary Kay Inc. Compositions comprising docynia delavajy extract and/or Elaeagnus lancelotus extract
CN104870001B (en) 2012-11-15 2019-01-18 赛博尔泰克股份公司 Delphinidin complex compound as anti-inflammatory or immunosupress effective component
US9511047B2 (en) * 2012-12-11 2016-12-06 Sapiotec Gmbh Delphinidin for combating melanoma cells
CN105616433A (en) * 2015-12-25 2016-06-01 中国农业大学 Medicine and functional food for inhibiting triple negative breast cancer
JP6961100B2 (en) * 2017-10-27 2021-11-05 ジェイビーケーラブ カンパニー リミテッドJbklab Co., Ltd. An immunopotentiator, an immunoanticancer agent, and a side effect relieving agent for an anticancer agent containing an anthocyanin-fucoidan complex as an active ingredient.
KR20210145207A (en) * 2019-03-29 2021-12-01 에보니크 오퍼레이션즈 게엠베하 Preparations containing berry extract for use in the prevention and/or treatment of viral infections caused by herpesvirida
CN110531011A (en) * 2019-09-27 2019-12-03 广州广电计量检测股份有限公司 A kind of detection method of 2,4- diamino anisole sulfate
CN114129605A (en) * 2021-08-27 2022-03-04 黑龙江联生生物科技有限公司 Application of blueberry anthocyanin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06271850A (en) * 1993-03-23 1994-09-27 Nikken Food Kk Antioxidant obtained from natural product as raw material and its production
JPH08104628A (en) * 1994-10-04 1996-04-23 Sumitomo Pharmaceut Co Ltd Inhibitor of matrix metalloprotease
WO1997041137A1 (en) * 1996-04-17 1997-11-06 Unifob Use of anthocyanidin and anthocyanidin derivatives
JP2000178295A (en) * 1998-12-17 2000-06-27 Lion Corp Antitumor composition
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
CN1408401A (en) * 2001-09-21 2003-04-09 赵春生 Cherry extract and its extracting method
JP2003277271A (en) * 2002-03-26 2003-10-02 Norioki Ko Anticancer drug

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06271850A (en) * 1993-03-23 1994-09-27 Nikken Food Kk Antioxidant obtained from natural product as raw material and its production
JPH08104628A (en) * 1994-10-04 1996-04-23 Sumitomo Pharmaceut Co Ltd Inhibitor of matrix metalloprotease
WO1997041137A1 (en) * 1996-04-17 1997-11-06 Unifob Use of anthocyanidin and anthocyanidin derivatives
JP2000178295A (en) * 1998-12-17 2000-06-27 Lion Corp Antitumor composition
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
CN1408401A (en) * 2001-09-21 2003-04-09 赵春生 Cherry extract and its extracting method
JP2003277271A (en) * 2002-03-26 2003-10-02 Norioki Ko Anticancer drug

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AFAQ FARRUKH ET AL: "Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 20 JAN 2005, vol. 113, no. 3, 28 September 2004 (2004-09-28), pages 423 - 433, XP002380735, ISSN: 0020-7136, Retrieved from the Internet <URL:www.interscience.wiley.com> [retrieved on 20060511] *
DATABASE WPI Section Ch Week 200348, Derwent World Patents Index; Class B04, AN 2003-505722, XP002380738 *
HAGIWARA A ET AL: "Pronounced inhibition by a natural anthocyanin, purple corn color, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-associated colorectal carcinogenesis in male F344 rats pretreated with 1,2-dimethylhydrazine", CANCER LETTERS, NEW YORK, NY, US, vol. 171, no. 1, 28 September 2001 (2001-09-28), pages 17 - 25, XP002305659, ISSN: 0304-3835 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 686 (C - 1292) 26 December 1994 (1994-12-26) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 08 30 August 1996 (1996-08-30) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 09 13 October 2000 (2000-10-13) *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Also Published As

Publication number Publication date
WO2006076387A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2006076387A3 (en) Cyanidin-3-glucoside as an anti-neoplastic agent
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1874920A4 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2007067682A3 (en) In vivo cell surface engineering
WO2011083088A3 (en) Methods for treating colorectal cancer
UA99833C2 (en) Pyrimidinyl pyridazinone derivates
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2007065010A3 (en) Anti-angiogenesis compounds
EP1940456A4 (en) Wwox gene, vectors containing the same, and uses in treatment of cancer
WO2005005601A8 (en) Compositions and methods for treating and diagnosing cancer
WO2012092420A3 (en) Methods for cryopreserving and encapsulating cells
MX2011011737A (en) Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase.
WO2008058239A9 (en) Spink1 as a prostate cancer marker and uses thereof
AU305421S (en) An electrode array
WO2010000364A8 (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
NO20064794L (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
WO2008112129A3 (en) Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
WO2009066353A1 (en) Power amplifier
WO2010065961A3 (en) Compositions and methods relating to mir-31
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
WO2007041564A3 (en) (s)-6-methyloxaalkyl exemestane compounds and related methods of use
PL1956896T3 (en) Cryopreservation of hepatocytes
WO2006113889A3 (en) Compositions and methods for modulating interleukin-10
HK1158076A1 (en) Composition useful for the prevention or reduction of the progression of prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06733673

Country of ref document: EP

Kind code of ref document: A2